Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant reduction in cardiovascular disease markers with good safety. The company plans to start Phase 2 trials for MRT-8102 in coronary artery disease, gout, and hidradenitis suppurativa in 2027. It also began a Phase 2 study of MRT-2359 for prostate cancer and received milestone payments from Novartis for advancing MRT-6160 into Phase 2 studies. Monte Rosa reported a Q3 net income of $3.1 million and holds $582.6 million in cash and equivalents, supporting operations through 2029.
Monte Rosa Therapeutics financial results provide context for health sector trading. For readers following health stocks, 94 of 150 US health stocks rose and 48 fell on Pluang. Notable movers as of Nov 05, 2026 19:01 WIB include BDX at USD 194.84 (-6.86%, 100% sell), IOVA at USD 9.20 (+5.75%, 52% buy), and ALMS at USD 6.20 (-5.34%).
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
